This study establishes a machine learning-optimized 3-gene prognostic signature (EGR3, RECQL4, MMP1) that bridges prognostic stratification and tumor-immune interplay in breast cancer, offering both clinical and mechanistic advancements. Here, RECQL4 is linked to neoplasm.